Teva eases debt burden with $400M tender offer as turnaround effort escalates
admin 7th September 2018 Uncategorised 0In February, Teva started the long climb back to health by restructuring its disastrous $40.5 billion purchase of Allergan’s generics unit, and now it’s cutting its debt load even more. But a successful turnaround will depend on the company’s ability to execute on its new products and late-stage pipeline, analysts say.
More: Teva eases debt burden with 0M tender offer as turnaround effort escalates
Source: fierce